Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection.

Fulcher JA, Tamshen K, Wollenberg AL, Kickhoefer VA, Mrazek J, Elliott J, Ibarrondo FJ, Anton PA, Rome LH, Maynard HD, Deming T, Yang OO.

Bioconjug Chem. 2019 Aug 21;30(8):2216-2227. doi: 10.1021/acs.bioconjchem.9b00451. Epub 2019 Jul 16.

PMID:
31265254
2.

Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.

Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM Jr, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.

PLoS Med. 2018 Sep 28;15(9):e1002655. doi: 10.1371/journal.pmed.1002655. eCollection 2018 Sep.

3.

Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.

Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Gunawardana M, Dawson LN, Olive TJ, Pyles RB, Baum MM.

PLoS One. 2018 Aug 22;13(8):e0201952. doi: 10.1371/journal.pone.0201952. eCollection 2018.

4.

Highly Attenuated Infection With a Vpr-Deleted Molecular Clone of Human Immunodeficiency Virus-1.

Ali A, Ng HL, Blankson JN, Burton DR, Buckheit RW 3rd, Moldt B, Fulcher JA, Ibarrondo FJ, Anton PA, Yang OO.

J Infect Dis. 2018 Sep 22;218(9):1447-1452. doi: 10.1093/infdis/jiy346.

5.

Comparative Assessment of Small and Large Intestine Biopsies for Ex Vivo HIV-1 Pathogenesis Studies.

Elliott J, Fulcher JA, Ibarrondo FJ, Tanner K, McGowan I, Anton PA.

AIDS Res Hum Retroviruses. 2018 Oct;34(10):900-906. doi: 10.1089/AID.2017.0249. Epub 2018 May 16.

6.

Brief Report: Recent Methamphetamine Use Is Associated With Increased Rectal Mucosal Inflammatory Cytokines, Regardless of HIV-1 Serostatus.

Fulcher JA, Shoptaw S, Makgoeng SB, Elliott J, Ibarrondo FJ, Ragsdale A, Brookmeyer R, Anton PA, Gorbach PM.

J Acquir Immune Defic Syndr. 2018 May 1;78(1):119-123. doi: 10.1097/QAI.0000000000001643.

7.

Human Semen or Seminal Plasma Does Not Enhance HIV-1BaL Ex Vivo Infection of Human Colonic Explants.

Kordy K, Elliott J, Tanner K, Johnson EJ, McGowan IM, Anton PA.

AIDS Res Hum Retroviruses. 2018 May;34(5):459-466. doi: 10.1089/AID.2017.0118. Epub 2018 Feb 21.

8.

Distinct aging profiles of CD8+ T cells in blood versus gastrointestinal mucosal compartments.

Dock J, Ramirez CM, Hultin L, Hausner MA, Hultin P, Elliott J, Yang OO, Anton PA, Jamieson BD, Effros RB.

PLoS One. 2017 Aug 23;12(8):e0182498. doi: 10.1371/journal.pone.0182498. eCollection 2017.

9.

Unique microRNA expression in the colonic mucosa during chronic HIV-1 infection.

Fulcher JA, Koukos G, Koutsioumpa M, Elliott J, Drakaki A, Iliopoulos D, Anton PA.

AIDS. 2017 Sep 10;31(14):1925-1934. doi: 10.1097/QAD.0000000000001582.

10.

Highly Human Immunodeficiency Virus-Exposed Seronegative Men Have Lower Mucosal Innate Immune Reactivity.

Fulcher JA, Romas L, Hoffman JC, Elliott J, Saunders T, Burgener AD, Anton PA, Yang OO.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):788-795. doi: 10.1089/AID.2017.0014. Epub 2017 Jun 19.

11.

Human immune compartment comparisons: Optimization of proliferative assays for blood and gut T lymphocytes.

Dock J, Hultin L, Hultin P, Elliot J, Yang OO, Anton PA, Jamieson BD, Effros RB.

J Immunol Methods. 2017 Jun;445:77-87. doi: 10.1016/j.jim.2017.03.014. Epub 2017 Mar 21.

12.

Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates.

Leyva F, Fuchs EJ, Bakshi R, Carballo-Dieguez A, Ventuneac A, Yue C, Caffo B, Du Y, Torbenson M, Li L, Mullin G, Lee L, Rohan L, Anton PA, Hendrix CW.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1089-97. doi: 10.1089/AID.2015.0086. Epub 2015 Jul 8.

13.

MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice.

Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, van der Meulen-de Jong AE, Oikonomopoulos A, van Deen WK, Vorvis C, Serebrennikova OB, Birli E, Choi J, Chang L, Anton PA, Tsichlis PN, Pothoulakis C, Verspaget HW, Iliopoulos D.

Gastroenterology. 2015 Oct;149(4):981-92.e11. doi: 10.1053/j.gastro.2015.05.057. Epub 2015 Jun 6.

14.

Exploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trials.

McGowan I, Anton PA, Elliott J, Cranston RD, Duffill K, Althouse AD, Hawkins KL, De Rosa SC.

PLoS One. 2015 May 26;10(5):e0126454. doi: 10.1371/journal.pone.0126454. eCollection 2015.

15.

A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).

Mcgowan I, Cranston RD, Duffill K, Siegel A, Engstrom JC, Nikiforov A, Jacobson C, Rehman KK, Elliott J, Khanukhova E, Abebe K, Mauck C, Spiegel HM, Dezzutti CS, Rohan LC, Marzinke MA, Hiruy H, Hendrix CW, Richardson-Harman N, Anton PA.

PLoS One. 2015 May 5;10(5):e0125363. doi: 10.1371/journal.pone.0125363. eCollection 2015.

16.

T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols.

Preza GC, Yang OO, Elliott J, Anton PA, Ochoa MT.

PLoS One. 2015 Apr 9;10(4):e0122723. doi: 10.1371/journal.pone.0122723. eCollection 2015.

17.

Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.

Richardson-Harman N, Hendrix CW, Bumpus NN, Mauck C, Cranston RD, Yang K, Elliott J, Tanner K, McGowan I, Kashuba A, Anton PA.

PLoS One. 2014 Oct 28;9(10):e111507. doi: 10.1371/journal.pone.0111507. eCollection 2014.

18.

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.

Yang KH, Hendrix C, Bumpus N, Elliott J, Tanner K, Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA, Kashuba AD.

PLoS One. 2014 Oct 28;9(10):e106196. doi: 10.1371/journal.pone.0106196. eCollection 2014.

19.

Seminal plasma HIV-1 RNA concentration is strongly associated with altered levels of seminal plasma interferon-γ, interleukin-17, and interleukin-5.

Hoffman JC, Anton PA, Baldwin GC, Elliott J, Anisman-Posner D, Tanner K, Grogan T, Elashoff D, Sugar C, Yang OO, Hoffman RM.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1082-8. doi: 10.1089/AID.2013.0217. Epub 2014 Oct 2.

20.

Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally.

Carballo-Diéguez A, Giguere R, Dolezal C, Bauermeister J, Leu CS, Valladares J, Rohan LC, Anton PA, Cranston RD, Febo I, Mayer K, McGowan I.

AIDS Behav. 2014 Sep;18(9):1734-45. doi: 10.1007/s10461-014-0793-0.

21.

Differential blood and mucosal immune responses against an HIV-1 vaccine administered via inguinal or deltoid injection.

Yang OO, Ibarrondo FJ, Price C, Hultin LE, Elliott J, Hultin PM, Shih R, Hausner MA, Ng HL, Hoffman J, Jamieson BD, Anton PA.

PLoS One. 2014 Feb 18;9(2):e88621. doi: 10.1371/journal.pone.0088621. eCollection 2014.

22.

Antigen-presenting cell candidates for HIV-1 transmission in human distal colonic mucosa defined by CD207 dendritic cells and CD209 macrophages.

Preza GC, Tanner K, Elliott J, Yang OO, Anton PA, Ochoa MT.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):241-9. doi: 10.1089/AID.2013.0145. Epub 2013 Dec 10.

23.

Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis.

Chatzaki E, Anton PA, Million M, Lambropoulou M, Constantinidis T, Kolios G, Taché Y, Grigoriadis DE.

World J Gastroenterol. 2013 Mar 7;19(9):1416-23. doi: 10.3748/wjg.v19.i9.1416.

24.

Preferential depletion of gut CD4-expressing iNKT cells contributes to systemic immune activation in HIV-1 infection.

Ibarrondo FJ, Wilson SB, Hultin LE, Shih R, Hausner MA, Hultin PM, Anton PA, Jamieson BD, Yang OO.

Mucosal Immunol. 2013 May;6(3):591-600. doi: 10.1038/mi.2012.101. Epub 2012 Nov 14.

25.

Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial.

Pines HA, Gorbach PM, Weiss RE, Hess K, Murphy R, Saunders T, Brown J, Anton PA, Cranston RD.

AIDS Behav. 2013 Mar;17(3):1002-15. doi: 10.1007/s10461-012-0358-z.

26.

Expression of corticotropin releasing factor receptor type 1 (CRF1) in the human gastrointestinal tract and upregulation in the colonic mucosa in patients with ulcerative colitis.

Yuan PQ, Wu SV, Elliott J, Anton PA, Chatzaki E, Million M, Taché Y.

Peptides. 2012 Nov;38(1):62-9. doi: 10.1016/j.peptides.2012.07.028. Epub 2012 Aug 28.

27.

RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.

Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, Elliott J, Janocko L, Khanukhova E, Dennis R, Cumberland WG, Ju C, Carballo-Diéguez A, Mauck C, McGowan I.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1412-21. doi: 10.1089/AID.2012.0262. Epub 2012 Oct 9.

28.

Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studies.

McGowan I, Tanner K, Elliott J, Ibarrondo J, Khanukhova E, McDonald C, Saunders T, Zhou Y, Anton PA.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1509-12. doi: 10.1089/AID.2012.0062. Epub 2012 Sep 4.

29.

Future prospects and perspectives on microbicides.

Anton PA.

Curr HIV Res. 2012 Jan 1;10(1):113-5.

30.

First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, Cortina G, Tanner K, Boscardin J, Cumberland WG, Zhou Y, Ventuneac A, Carballo-Diéguez A, Rabe L, McCormick T, Gabelnick H, Mauck C, McGowan I.

PLoS One. 2011;6(9):e23243. doi: 10.1371/journal.pone.0023243. Epub 2011 Sep 28.

31.

Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations.

Wang L, Schnaare RL, Dezzutti C, Anton PA, Rohan LC.

AIDS Res Ther. 2011 Mar 7;8:12. doi: 10.1186/1742-6405-8-12.

32.

HIV Infection and Gut Mucosal Immune Function: Updates on Pathogenesis with Implications for Management and Intervention.

Shacklett BL, Anton PA.

Curr Infect Dis Rep. 2010 Jan;12(1):19-27. doi: 10.1007/s11908-009-0072-9. Epub 2010 Jan 13.

33.

Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis.

Richardson-Harman N, Lackman-Smith C, Fletcher PS, Anton PA, Bremer JW, Dezzutti CS, Elliott J, Grivel JC, Guenthner P, Gupta P, Jones M, Lurain NS, Margolis LB, Mohan S, Ratner D, Reichelderfer P, Roberts P, Shattock RJ, Cummins JE Jr.

J Clin Microbiol. 2009 Nov;47(11):3530-9. doi: 10.1128/JCM.00673-09. Epub 2009 Sep 2.

34.

Assessment of a primary and tertiary care integrated management model for chronic obstructive pulmonary disease.

Bolíbar I, Plaza V, Llauger M, Amado E, Antón PA, Espinosa A, Domínguez L, Fraga M, Freixas M, de la Fuente JA, Liguerre I, Medrano C, Peiro M, Pou M, Sanchis J, Solanes I, Valero C, Valverde P; COPD PROCESS Study Group.

BMC Public Health. 2009 Feb 24;9:68. doi: 10.1186/1471-2458-9-68.

35.

Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome.

Chang L, Sundaresh S, Elliott J, Anton PA, Baldi P, Licudine A, Mayer M, Vuong T, Hirano M, Naliboff BD, Ameen VZ, Mayer EA.

Neurogastroenterol Motil. 2009 Feb;21(2):149-59. doi: 10.1111/j.1365-2982.2008.01171.x. Epub 2008 Aug 5.

36.

Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.

Anton PA, Ibarrondo FJ, Boscardin WJ, Zhou Y, Schwartz EJ, Ng HL, Hausner MA, Shih R, Elliott J, Hultin PM, Hultin LE, Price C, Fuerst M, Adler A, Wong JT, Yang OO, Jamieson BD.

Vaccine. 2008 Aug 18;26(35):4617-23. doi: 10.1016/j.vaccine.2008.05.084. Epub 2008 Jun 17.

37.

Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056).

McGowan I, Elliott J, Cortina G, Tanner K, Siboliban C, Adler A, Cho D, Boscardin WJ, Soto-Torres L, Anton PA.

J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):417-25.

PMID:
17891044
38.

Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals.

Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, McGowan I, Brown S, Anton PA.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):65-8.

PMID:
16936559
39.

Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response".

Jamieson BD, Ibarrondo FJ, Wong JT, Hausner MA, Ng HL, Fuerst M, Price C, Shih R, Elliott J, Hultin PM, Hultin LE, Anton PA, Yang OO.

Vaccine. 2006 Apr 24;24(17):3426-31. Epub 2006 Mar 3.

PMID:
16545508
40.

Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa.

Gurney KB, Elliott J, Nassanian H, Song C, Soilleux E, McGowan I, Anton PA, Lee B.

J Virol. 2005 May;79(9):5762-73.

41.

An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial.

Seidner DL, Lashner BA, Brzezinski A, Banks PL, Goldblum J, Fiocchi C, Katz J, Lichtenstein GR, Anton PA, Kam LY, Garleb KA, Demichele SJ.

Clin Gastroenterol Hepatol. 2005 Apr;3(4):358-69.

PMID:
15822041
42.

Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection.

Ibarrondo FJ, Anton PA, Fuerst M, Ng HL, Wong JT, Matud J, Elliott J, Shih R, Hausner MA, Price C, Hultin LE, Hultin PM, Jamieson BD, Yang OO.

J Virol. 2005 Apr;79(7):4289-97.

43.

Inflammatory bowel disease and irritable bowel syndrome: separate or unified?

Bradesi S, McRoberts JA, Anton PA, Mayer EA.

Curr Opin Gastroenterol. 2003 Jul;19(4):336-42.

PMID:
15703574
44.

Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?

Newman PA, Duan N, Rudy ET, Anton PA.

AIDS Patient Care STDS. 2004 Dec;18(12):691-701. Review.

PMID:
15659880
45.

Optimization of methods to assess human mucosal T-cell responses to HIV infection.

Shacklett BL, Yang O, Hausner MA, Elliott J, Hultin L, Price C, Fuerst M, Matud J, Hultin P, Cox C, Ibarrondo J, Wong JT, Nixon DF, Anton PA, Jamieson BD.

J Immunol Methods. 2003 Aug;279(1-2):17-31.

PMID:
12969544
46.

Mucosal immunity and vaccination against HIV.

Lehner T, Anton PA.

AIDS. 2002;16 Suppl 4:S125-32. Review. No abstract available.

PMID:
12699009
47.

Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects.

Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM.

AIDS. 2003 Jan 3;17(1):53-63.

PMID:
12478069
48.

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM.

Mol Ther. 2002 Jun;5(6):788-97.

49.

Supplemental Content

Loading ...
Support Center